CenterWatch

Clinical Trial Details

Overview

Research Study Summary

A 6 month, randomized, active comparator, open-label, multi-center study to evaluate patient outcomes, safety and tolerability of Fingolimod (FTY720) 0.5mg/day in patients with relapsing remitting MS who are candidates for MS therapy change from previous disease modifying therapy (EPOC).

Purpose

The purpose of this study is to evaluate patient-reported outcomes and physician assessment of a change in therapy for patients with remitting-relapsing multiple sclerosis when changing a patient's current multiple sclerosis therapy to fingolimod or maintaining the current therapy.

Please contact Alexian Brothers for more information on participation.

To Learn more

CW ID: 176860
Date Last Changed: July 22, 2013

Clinical Trial Snapshot

Phase
4
Gender
Both Male and Female
Age
N/A
Overall Status
Recruiting
Duration
6 Months
Facility Type
N/A

Contact

Alexian Brothers Hospital Network
800 Biesterfield Road Brock Building First Floor
Elk Grove Village, IL 60007
Phone: 847-593-8553

View Map

Research Center Information: Alexian Brothers Hospital Network

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.